GENOMICA S.A.U. of Madrid at MEDICA 2018 in Düsseldorf -- MEDICA - World Forum for Medicine

GENOMICA S.A.U.

Parque Empresarial Alvento, Edificio B, Vía de los Poblados 1, 1ª Planta, 28033 Madrid
Spain
Telephone +34 91 6748990
Fax +34 91 6748991
info.genomica@genomica.com

This company is co-exhibitor of
SCIENION AG

Hall map

MEDICA 2018 hall map (Hall 3): stand A42

Fairground map

MEDICA 2018 fairground map: Hall 3

Our range of products

Product categories

  • 03  Diagnostics
  • 03.06  Genetic testing, molecular diagnostics
  • 03.06.03  Polymerase chain reaction (PCR)

Polymerase chain reaction (PCR)

Our products

Product category: Polymerase chain reaction (PCR)

CLART (Clinical Array Technology)

CLART® is a low density microarray-based platform for clinical
use that allows the detection of multiple targets in a single
test. Sample processing is straightforward and the analysis
and interpretation of results are performed automatically by a
reader (CAR® or CLINICAL ARRAY READER) running tailor-made
software. Its simplicity makes this technology suitable for every
molecular diagnostics laboratory.

CLART® provides fast, sensitive and accurate results that meet
the highest quality standards, and allows the clinician to take the
right decisions on time.

CLART is divided in Microbiology kits for diverse pathogenes detection and an Oncology line named CLART CMA to detect mutations in oncogenes.  

More Less

About us

Company details

GENOMICA is the first Spanish company in Molecular Diagnostics that develops and manufactures CLART, its own line of IVD kits. The company is currently commercializing them in more than 40 countries worldwide and dispose of subsidiaries offices in China, Brazil, and Sweden. The company is a reference globally as a reliable and competitive kits supplier. Its kits are used in screening programs under its own brand. Also, it has OEM agreements with international brands. 

GENOMICA is committed to the highest quality standards and put a huge effort into research and development. The company is now working in a breakthroug development: NEDxA, its very first POCT device.

More Less